HCV Trials | UW Division of Gastroenterology | University of Washington

UW Division of Gastroenterology University of Washington

Research

UW Division of Gastroenterology

HCV - Hepatitis C Virus

REGISTRY/OBSERVATION STUDY

HCV - TARGET
Title: Hepatitis C Therapeutic Registry and Research Network - A Longitudional, Observational Study
Condition & Intervention: HCV - patients being treated with treatments containing telaprvir or boceprevir
PI: Landis
Site: HMC

OPEN-LABEL TREATMENT STUDIES

HCV Pro00069602
Title: A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease
Condition and Intervention: Hep C, Heart Failure, Chronic Pulmonary Disease, Interstitial Lung Disease: Harvoni/Sofosbuvir/Ledipasvir
PI: Landis
Site: HMC

HCV B16-439
Title: A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Condition & Intervention: Hepatits C, HCV: Glacaprevir/Pibrentasvir 300mg, Ribavirin 200mg, Sofosbuvir 400mg (oral)
PI: Landis
Site: HMC

Innovation & Discovery

C-LIFE-2.jpg

ELIGIBILITY FOR CLINICAL TRIALS

If you have a patient* that might be eligible for one of our clinical trials, please send an email to HepTrial@uw.edu with the following information:

Patient Name and MRN
Diagnosis
Any treatment received/provided
Current Liver Biopsy - yes/no
Other relevant Information

*By submitting the patient's information to C-LIFE, you agree that our research team may contact the patient directly about clinical trials, if appropriate.